Work

Pembrolizumab-Induced Rhabdomyolysis in a Clear Cell Renal Cell Carcinoma Patient: A Case Report

Year: 2023

Type: article

Abstract: Pembrolizumab is one of the approved treatments for many types of cancer including clear cell renal cell carcinoma (ccRCC). It has improved the prognosis of renal cell carcinoma, yet has many possible immune-related side effects. We discuss a rare case of rhabdomyolysis in an ccRCC patient treated with pembrolizumab. The case was complicated with acute kidney injury and severe hypothyroidism, which can be attributed to pembrolizumab.

Source: Case Reports in Oncology

DOI: 10.1159/000532100

Authors: Mohammad Altermanini, Khaled Ali, Wisam Alwassiti, Suliman Almohtasib, Nabil E. Omar, Abdulaziz Zafar

Institutions: Hamad Medical Corporation, National Center for Cancer Care and Research, Qatar University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,170